RT @COREIMpodcast: 1/ 🚨 NEW #BeyondJournalClub w/ @NEJMGroup: REDUCE-AMI . What is the long term benefit of beta blockers in patients with….

RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa….

RT @Bweber04: A wonderful evening w so many celebrations but most importantly @RonBlankstein on his mentorship to all and his well deserved….

RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/….

RT @NEJM: Original Article: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension (Advance-HTN trial) .

RT @zakkohane: Most interestingly GPT‑4.1 nano outperformed GPT-4o. This suggests that the nose-dive in costs for AI solutions will contin….

RT @JAMAInternalMed: LLM-generated discharge summaries were of comparable quality to those generated by physicians, though they contained m….

RT @FedericaFogacci: Great to meet up w/ EAS YF at #EASCongress2025! Always inspiring to connect w/ colleagues 🌍, and honored to have Profs….

RT @NEJM: A 65-year-old man presented with a 1-day history of an itchy rash on his hip. A clinical diagnosis of southern tick-associated ra….

RT @ChaturvediNeuro: Interesting debate in @NEJM on optimal treatment of device detected A FIB @SposatoL @CSC_Stroke @Ash_Shoamanesh .https….

Would you prescribe beta blockers to this patient who’s had a #heartattack? Voting is open for two more weeks on @NEJM. It was a real pleasure to write this #ClinicalDecisions with David Maron from @StanfordDeptMed and Tomas Jernberg from @karolinskainst

RT @DFCapodanno: I created this short animation to illustrate which drugs are currently under investigation and appear most promising in ta….

RT @ehj_ed: Coronary inflammation and cardiovascular risk in breast cancer after radiotherapy. Read more in #EHJ.@e….

RT @RCH_MD: Fascinating data—could the atherogenic #inflammation and CAD risk in #BreastCancer patients be mediated more by the tumor itsel….

5/ Big thanks to my mentor @Charis_Oxford @UniofOxford and Sophie Jacob @IRSNFrance @ASNR_Fr #CardioTwitter #EHJ #CardioOncology.

4/💡We saw a parallel increase in coronary calcification suggesting plaque stabilization as coronary inflammation is resolved, supporting the notion that high coronary inflammation at baseline may be driven by the tumour itself, which is reduced as the tumour is treated with RT.

3/ At baseline, women had very high coronary inflammation across all three #coronaries - much higher than matched controls. After 2 years:.✅ Inflammation decreased.✅ AI-Risk dropped.

2/ RT in breast cancer has long been feared to increase heart risk via #coronary inflammation. But our latest study challenges that concept. We followed 105 women with #BreastCancer , all treated with RT (no #chemo). They had coronary #yesCCT before and 2 years after RT.

1/ New research🫀.Our latest report highlights a significant reduction in coronary #inflammation and residual inflammatory risk as captured by #yescct imaging using CaRi-Heart AI in women with #BreastCancer 2 years post-RT: �👇.#AI #CardioOnc @ehj_ed.

RT @NEJM: Original Article: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis (REGENCY phase 3 trial) .